Anapharm Europe
Anapharm Europe is recorded as a service provider in 26 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 26 trials · Latest update first
A multicenter, open-label, non-randomized Phase 1/2 study to assess safety, tolerability, and imaging characteristics of [68Ga]Ga-DPI-4452 and to assess safety, tolerability, and efficacy of [177Lu]Lu-DPI-4452 in patients with unresectable locally advanced or metastatic solid tumors
Sponsor ITM Oncologics GmbH
- Start (EU)
- Latest update
- Estimated end
An Exploratory, Multi-Centre, Interventional, Prospective, Randomised, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of AON-D21 in Patients with Severe Community-Acquired Pneumonia.
Sponsor Aptarion Biotech AG
- Start (EU)
- Latest update
- Estimated end
Phase 1b/2 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, in combination with regorafenib and tislelizumab in patients with advanced/metastatic colorectal cancer
Sponsor Oncomatryx Biopharma S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Randomized, Open-Label, Single-Dose, Parallel-Group Study to Evaluate the Relative Bioavailability of LY03010 versus Xeplion® after Intramuscular Injection in Healthy Subjects
Sponsor Geneora Pharma (Shijiazhuang) Co. Ltd.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available3 trial-level findings · Read insights
- The single study center in Porto, Portugal enrolled 170 participants after screening 645 participants.
- A pre-randomization oral risperidone tolerability test was required, and subjects with hypersensitivity or high sensitivity to risperidone were excluded before investigational-product treatment.
- Participants underwent 23 venous blood collections through Day 148 (Week 21) after dosing.
These findings describe the trial, not the service provider’s performance or responsibility.
Randomized, Double-blind, Placebo-controlled, Proof-of-concept Phase II Trial Investigating the Effect of Valproic Acid in Women with Adenomyosis.
Sponsor CCDRD Cooperative Clinical Drug Research and Development AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
Bioequivalence of Apixaban 5 mg Film-Coated Tablets: A Single-Dose, Open-Label, Randomized, Two-Sequence, Two-Treatment, Two-Period Crossover Study in Healthy Subjects Under Fasting Conditions.
Sponsor Laboratorios Cinfa S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomized, double-blind, vehicle-controlled, multi-centre, parallel-group study to investigate the safety, tolerability, and efficacy of GR1014 cutaneous gel as a topical radioprotector in the prevention of the radiodermatitis occurring with adjuvant radiotherapy for localized breast cancer after lumpectomy
Sponsor Graegis Pharmaceuticals Limited
- Start (EU)
- Latest update
- Estimated end
A single-centre, randomized, double blind, placebo controlled, crossover, single dose clinical trial to compare orodispersible presentations of bilastine, ebastine, and desloratadine in the suppression of wheal and flare induced by intradermal histamine in healthy volunteers.
Sponsor Faes Farma S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM14 in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors
Sponsor Pharma Mar S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors
Sponsor Pharma Mar S.A.
- Start (EU)
- Latest update
- Estimated end
Randomised, bioequivalence clinical trial of ezetimibe/atorvastatin 10 mg/40 mg tablets versus ezetimibe/atorvastatin 10 mg/40 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions in crossover replicated design
Sponsor Laboratorios Normon S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomised, double-blind, multicentre, international placebo-controlled phase II study aimed at investigating the efficacy and safety of a novel modified-release tablet formulation of colesevelam hydrochloride in patients with bile acid diarrhoea (BAD)
Sponsor Cosmo Technologies Limited
- Start (EU)
- Latest update
- Estimated end
Randomised, bioequivalence clinical trial of ezetimibe/atorvastatin 10 mg/80 mg tablets versus ezetimibe/atorvastatin 10 mg/80 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions in crossover replicated design.
Sponsor Laboratorios Normon S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomized, double-blind, placebo-controlled, Phase 2 study to assess the efficacy, safety, and pharmacokinetics of FNP-223 (oral formulation) to slow the disease progression of progressive supranuclear palsy (PSP) PROSPER
Sponsor Ferrer Internacional S.A.
- Start (EU)
- Latest update
- Estimated end
Comparative Bioavailability of Empagliflozin 25 mg Film-Coated Tablets: A Single-Dose, Open-Label, Randomized, Two-Sequence, Two-Treatment, Two-Period Crossover Study in Healthy Subjects Under Fasting Conditions.
Sponsor Tecnimede-Sociedade Tecnico-Medicinal S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination with Irinotecan versus Investigator’s Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer (SCLC) Patients (LAGOON Trial)
Sponsor Pharma Mar S.A.
- Start (EU)
- Latest update
- Estimated end
Randomised bioequivalence clinical trial of sacubitril/valsartan 97 mg/103 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions in crossover replicated design.
Sponsor Laboratorios Normon S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Randomised bioequivalence clinical trial of sacubitril/valsartan 49 mg/51 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions in crossover replicated design.
Sponsor Laboratorios Normon S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Randomised, crossover bioequivalence clinical trial of hydrochlorothiazide 25 mg tablets, after a single oral dose administration to healthy volunteers under fasting conditions.
Sponsor Laboratorios Normon S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Randomised, crossover bioequivalence clinical trial of ezetimibe/atorvastatin 10 mg/80 mg tablets versus ezetimibe/atorvastatin 10 mg/80 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions
Sponsor Laboratorios Normon S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Anapharm Europe?
The 2026-10-09 snapshot links Anapharm Europe to 26 distinct CTIS trials. Recorded services include Laboratory services, Analysis of drug concentrations, immunogenicity analysis (antibody anti-drug or ADA detection), Biomarker Assessment. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Anapharm Europe?
The most frequently recorded therapeutic areas are Gastroenterology, Neurology, Respiratory, Solid Tumor Oncology. Recorded phases include Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Anapharm Europe conducted?
The linked trials record locations in 12 countries, including Spain, France, Portugal, Belgium, Italy. These are trial locations, not confirmed office locations or countries where Anapharm Europe delivered services.
What can this page tell me about Anapharm Europe's trial experience?
Browse 26 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Anapharm Europe. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Anapharm Europe S.L.